Letter from Dr. Maycock Lister Institute of Preventive Medicine to Dr. D.P. Thomas at Department of Health and Social Security. The letter concerns product licence applications for Hemofil and Kryobulin. Maycock states his view that the DHSS should initially restrict the use of these two products to selected haemophilia centres so they can be critically examined for efficacy.